- Home
- STGW vs RCUS Comparison
STGW vs RCUS Comparison
Compare STGW & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STGW
- RCUS
- Stock Information
- Founded
- STGW 1980
- RCUS 2015
- Country
- STGW United States
- RCUS United States
- Employees
- STGW N/A
- RCUS N/A
- Industry
- STGW
- RCUS Biotechnology: Pharmaceutical Preparations
- Sector
- STGW
- RCUS Health Care
- Exchange
- STGW Nasdaq
- RCUS Nasdaq
- Market Cap
- STGW 1.4B
- RCUS 1.2B
- IPO Year
- STGW N/A
- RCUS 2018
- Fundamental
- Price
- STGW $5.45
- RCUS $14.94
- Analyst Decision
- STGW Buy
- RCUS Buy
- Analyst Count
- STGW 5
- RCUS 7
- Target Price
- STGW $8.17
- RCUS $22.00
- AVG Volume (30 Days)
- STGW 1.2M
- RCUS 937.9K
- Earning Date
- STGW 11-06-2025
- RCUS 11-05-2025
- Dividend Yield
- STGW N/A
- RCUS N/A
- EPS Growth
- STGW N/A
- RCUS N/A
- EPS
- STGW N/A
- RCUS N/A
- Revenue
- STGW $2,858,547,000.00
- RCUS $262,000,000.00
- Revenue This Year
- STGW $4.85
- RCUS N/A
- Revenue Next Year
- STGW $8.79
- RCUS N/A
- P/E Ratio
- STGW N/A
- RCUS N/A
- Revenue Growth
- STGW 9.37
- RCUS 6.07
- 52 Week Low
- STGW $4.03
- RCUS $6.50
- 52 Week High
- STGW $8.18
- RCUS $18.98
- Technical
- Relative Strength Index (RSI)
- STGW 49.51
- RCUS 72.52
- Support Level
- STGW $5.26
- RCUS $12.89
- Resistance Level
- STGW $5.64
- RCUS $16.12
- Average True Range (ATR)
- STGW 0.19
- RCUS 0.72
- MACD
- STGW 0.00
- RCUS 0.09
- Stochastic Oscillator
- STGW 61.40
- RCUS 57.70
About STGW Stagwell Inc.
Stagwell Inc is the challenger holding company built to transform marketing. It delivers scaled creative performance for the world's ambitious brands, connecting culture-moving creativity with a technology to harmonize the art and science of marketing. The company's segments include Integrated Agencies Network; Brand Performance Network; and Communications Network. It generates maximum revenue from the Integrated Agencies Network segment. Geographically, it derives a majority of its revenue from the United States.
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.